Apheresis technology for prevention and regression of atherosclerosis: An overview

Therapeutic Apheresis

Volumn 1, Issue 3, 1997, Pages 233-241

  Yamamoto, Akira ^a,b   Kawaguchi, Akito ^a   Harada Shiba, Mariko ^a   Tsushima, Motoo ^a   Kojima, Shun Ichi ^a,c  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Mino o Life Plaza   (Japan)

^c SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Aortic stenoregurgitation; Bradykinin; Familial hypercholesterolemia; LDL apheresis; Lipoprotein (a); Low density lipoprotein

Indexed keywords

CELLULOSE; DEXTRAN SULFATE; LOW DENSITY LIPOPROTEIN; PLASMA SUBSTITUTE;

APHERESIS; ARTERIOSCLEROSIS; BLOOD; FOLLOW UP; HUMAN; METHODOLOGY; REVIEW; TREATMENT OUTCOME;

ARTERIOSCLEROSIS; BLOOD COMPONENT REMOVAL; CELLULOSE; DEXTRAN SULFATE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, LDL; PLASMA SUBSTITUTES; TREATMENT OUTCOME;

EID: 0031195812     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1997.tb00144.x     Document Type: Review

References (60)

1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years follow up from the Framingham Study. JAMA 1987;257:2176-80.
2. Stamler J, Wentworth D, Neaton JD for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Finding in 356,222 primary screenees of the multiple risk factors intervention trial. JAMA 1986;256:2823-8.
3. Yamamoto A. Regression of atherosclerosis in humans by lowering serum cholesterol (Review). Atherosclerosis 1991;89: 1-10.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
6. Yamamoto A, Kamiya T, Yamamura T, Yokoyama S, Horiguchi Y, Funahashi T, Kawaguchi A, Miyake Y, Beppu S, Ishikawa K, Matsuzawa Y, Takaichi S. Clinical features of familial hypercholesterolemia. Arteriosclerosis 1989;9:66-74.
7. Deckelbaum RJ, Lees RS, Small DM, Hedberg SE, Grundy SM. Failure of complete bile acid diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia. N Engl J Med 1977;296:465-70.
8. DeGenne JL, Toutaine R, Maunand B, Truffert J, Laudat P. Forme homozygotes cutanneo-tendineuses de xanthomatose hypercholesterolemique dans une observation famiale exemplaire. Essai de plasmapherese a titre de traitment heroique. Bull Mem Soc Hop Paris 1967;118:1377-402.
9. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Brit Med J 1985;291:1671-3.
10. Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, Steiner RE. Assessment of long-term plasma exchange for familial hypercholesterolemia. Brit Heart J 1980; 43:680-8.
11. Lupien P-J, Moorjani S, Gagne C, Brun LD, Lou M, Gagne G. Long term treatment of two familial hypercholesterolemic heterozygote patients with batch affinity chromatography (BAC). Artery 1982;10:286-300.
12. Keller C, Schmitz H, Theisen K, Zollner N. Regression of valvular aortic stenosis due to homozygous familial hypercholesterolemia following plasmapheresis. Klin Wschr 1986;64: 3338-41.
13. Yokoyama S, Yamamoto A, Hayashi R, Satani M. LDL-apheresis; Potential procedure for prevention and regression of atheromatous vascular lesion. Jpn Circ J 1987;51:1116-22.
14. Minakata T, Fukasawa A, Fujiwara S. Treatment of familial hypercholesterolemia using double filtration plasmapheresis. In: Oda T, ed. Therapeutic plasmapheresis III (Proceedings of the III Symposium of the Japanese Society for Therapeutic Plasmapheresis) Stuttgart: Schattauer, 1983:109-12.
15. Koga N, Nomura G, Yamagata Y, Takada S, Nishimura T, Sanada A, Kanaya S, Fujino T. Double filtration plasmapheresis in the treatment of two cases of homozygous familial hypercholesterolemia. In: Oda T., ed. Therapeutic plasmapheresis III (Proceedings of the III Symposium of the Japanese Society for Therapeutic Plasmapheresis) Stuttgart: Schattauer, 1983:113-8.
16. Kikkawa T, Yokoyama S, Hayashi R, Yamamoto A, Satani M, Kishino B. Specificity of various plasmapheresis techniques for treatment of hypercholesterolemia. In: Shiokawa Y, Inoue N, eds. Current practice in therapeutic plasmapheresis. Amsterdam: Excerpta Medica (Int Congr Ser 694) 1985: 144-51.
17. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Specific removal of low-density-lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5:613-22.
18. Yamamoto A, Yokoyama S, Kojima S, Kawaguchi A, Bosch T. Comparison of double membrane filtration and affinity chromatographic techniques. In: Lock G, ed. Apheresis. New York: Wiley-Liss, 1990:613-22.
19. Lupien P-J, Moorjani S, Awad J. A new approach to the management of familial hypercholesterolemia; removal of plasma cholesterol based on the principle of affinity chromatography. Lancet 1975;1:1261-4.
20. Yokoyama S, Hayashi R, Kikkawa T, Tani N, Takada S, Hatanaka K, Yamamoto A. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis (LA-01); characterization and experimental use for hypercholesterolemic rabbits. Arteriosclerosis 1984;4:276-82.
21. Tani N. Development of LDL-apheresis (Liposorber system). Igaku-no Ayumi (J Clin Exp Med) 1991;157:723-8 (in Japanese).
22. Takada S, Tani N, Ohnishi M, Kau A, Narisada U. Automated continuous low density lipoprotein adsorption system. In: Oda T, ed. Therapeutic plasmapheresis VII (Proceedings of the VII Symposium of the Japanese Society for Therapeutic Plasmapheresis) Cleveland: ISAO Press, 1988:454-9.
23. Kawaguchi A, Yokoyama S, Kojima S, Yamamoto A. Sieving of low density lipoprotein at low blood and plasma flow rates through polysulfone hollow fibre filter. In: Oda T, ed. Therapeutic Plasmapheresis VII (Proceedings of the VII Symposium of the Japanese Society for Therapeutic Plasmapheresis) Stuttgart: Schattauer, 1987:254-6.
24. Hatanaka K, Uchida K, Sakai H, Kurata M, Li X, Yamamoto A. The effect of low density lipoprotein apheresis on plasma thrombomodulation system. ASAIO J 1992;38:102-7.
25. Armstrong VW, Windisch M, Wieland H, Fuchs C, Rieger J, Köstering H, Nebendahl K, Scheler F, Seidel D. Selective continuous elimination of low-density lipoproteins with heparin at acidic pH. Trans Am Soc Artif Intern Organs 1983;29: 323-7.
26. Schuff-Werner P, Schuetz E, Seyde WC, Eisenhauer T, Jannings G, Armstrong VW, Seidel D. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation. Eur J Clin Invest 1989;19:30-7.
27. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D, and the HELP-Study Group. The HELP-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II Final evaluation of the effect of regular treatment on LDL-cholesterol concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
28. Stoffel W, Demant T. Selective removal of apolipoprotein B-containing lipoprotein from blood plasma. Proc Natl Acad Sci USA 1981;78:611-5.
29. Saal SD, Parker TS, Gordon BR, Studebaker J, Hudgins L, Ahrens EH Jr, Rubin AC. Removal of low density lipoproteins in patients by extracorporeal immunoadsorption. Am J Med 1986;80:583-9.
30. Pokrovsky SN, Sussakov AV, Adamova IY, Afanasieva OI, Benevolenskaya GF, Konovalov CA, Kukharchuk UV. Development of immunoadsorbents for apo B-containing lipoproteins apheresis. Artif Organs 1995;19:500-5.
31. Yamamoto A, Kojima S, Shiba-Harada A, Kawaguchi A, Hatanaka K. Assessment of biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. Artif Organs 1992;16:177-81.
32. Kojima S, Harada-Shiba M, Toyota Y, Kimura G, Tsushima M, Kuramochi M, Sakata T, Uchida K, Yamamoto A, Omae T. Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992;15:185-90.
33. Yamamoto A, Yokoyama S, Satani M, Kikkawa T, Kishino B. Evaluation of selective LDL-removal in the treatment of familial hypercholesterolemia: double membrane filtration and adsorption. In: Agishi T, Kawamura A, Mineshima M, eds. Progress in clinical biological research, vol 255, Recent aspects of diagnosis and treatment of lipoprotein disorders: Impact on prevention of atherosclerosis diseases. New York: Alan R Liss, 1988:357-66.
34. Kojima S, Harada-Shiba M, Toyota Y, Murakami K, Kimura G, Tsushima M, Kuramochi M, Yamamoto A, Omae T. Evaluation of cholesterol and Lp(a) removal by low density lipoprotein apheresis. In: Widhalm K, Naito HK, eds. Therapeutic plasmapheresis XII (Proceedings of the XII Symposium of the Japanese Society for Therapeutic Plasmapheresis) Utrecht: VSP, 1993:411-3.
35. Daida H, Young JL, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takasu F, Kato H, Kutsumi Y. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(s) levels with low-density lipoprotein apheresis. Am J Cardiol 1994;73:1037-40.
36. Kojima S, Shiba M, Yamamoto A, Kojima K, Tani N. Changes of serum amyloid proteins during LDL apheresis. Jpn J Apheresis 1995;14:113-4.
37. Kaneka America Corporation. Liposorber LA-15 System Operators Manual, I8-10.
38. Olbricht CJ, Schauman D, Fisher D. Anaphylactoid reactions, LDL apheresis with dextran sulfate, and ACE inhibitors. Lancet 1992;340:908-9.
39. Agishi T. Anion-blood contact reaction (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors. JAMA 1994; 271:195-6.
40. Keller C, Grutzmacher P, Bair F, Schwarzbeck A, Kroon AA, Kiral A. LDL-apheresis with dextran sulfate and anaphylactoid reactions to ACE inhibitors. Lancet 1993;341:60.
41. Kojima S, Harada-Shiba M, Nomura S, Kimura G, Tsushima M, Kuramochi M, Yamamoto A, Omae T. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. ASAIO Trans 1991;37:644-8.
42. Agishi T, Kitano Y, Suzuki T, Miura A. Improvement of peripheral circulation by low density lipoprotein adsorption. Trans Am Soc Artif Intern Organs 1989;35:349-51.
43. Naganuma S, Agishi T, Ota K. LDL apheresis in atherosclerotic disease with hyperlipidemia. ASAIO J 1992;38:M436-9.
44. Sato Y, Agishi T. Low-density lipoprotein adsorption for atherosclerotic patients. Artif Organs 1996;20:324-7.
45. Egashira K, Takeshita A. Beneficial effect of cholesterol-lowering therapy on endothelium-dependent coronary vasodilatation in patients with hypercholesterolemia. Ann NY Acad Sci 1995;748:622-5.
46. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
47. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL-apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
48. Hombach V, Borberg H, Gadzkowski A, Oette K, Stoffel W. Regression der Koronarsklerose bei familiarer Hypercholesterinamie IIa durch spezifische LDL-Apherese. Deut Med Wshr 1986;111:1709-15.
49. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A for the LARS Investigators. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia; a multicenter study. Atherosclerosis 1992;95: 1-13.
50. Nishimura S, Yamaguchi H, L-CAPS Group Investigators. Regression of coronary atherosclerosis by intensive lipid-lowering therapy with combined LDL-apheresis and drugs in familial hypercholesterolemia; Japan LDL-Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Circulation 1994;90 (4, 2):I510 (abstract).
51. Koga N, Sato T, Kurashige Y, Nagano T, Hashizume K, Iwamoto H. Long-term effects of LDL apheresis on coronary and carotid atherosclerosis in familial hypercholesterolemic patients. In: Yamamoto A, ed. Therapeutic plasmapheresis XVI (Proceedings of the first International Conference for Apheresis with the XVI Symposium of the Japanese Society for Apheresis) Japanese Society for Apheresis, 1997:63-8.
52. Hennerici M, Kleophas W, Gries FA. Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke 1991;22:989-92.
53. Yamamoto A, Kojima S, Harada-Shiba M, Toyota Y, Takamiya M, Tsushima M, Kishino B, Koga N, Tatami R. Plasmapheresis for prevention and regression of coronary atherosclerosis. Ann NY Acad Sci 1995;748:429-40.
54. Borberg H. Fifteen years experience with LDL-apheresis. In: Yamamoto A, ed. Therapeutic plasmapheresis XVI (Proceedings of the first International Conference for Apheresis in conjunction with the XVI Symposium of the Japanese Society for Apheresis) Japanese Society for Apheresis 1997:56-62.
55. Kroon AA, Aengevaeren WRM, van der Werf T, Uijen GJH, Reiber HC, Bruschke AVG, Stalenhoef AFH. LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
56. Thompson GR, Maher VMG, Mattews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial hypercholesterolemia regression study: A randomized trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
57. Harada-Shiba M, Yamamura T, Toyota Y, Tsushima M, Kojima S, Yamamoto A. Kinetic analysis of cholesterol and Lp(a) using the rebound curve after LDL-apheresis. Jpn J Apheresis 1996;15:96-7.
58. Harada-Shiba M, Yamamura T, Toyota Y, Tsushima M, Kojima S, Yamamoto A. Rebound curve following LDL-apheresis reflects catabolic rate of plasma cholesterol and the synthetic rate of Lp(a). In: Gotto AM Jr, Paoletti R, Smith LC, Catapano AL, Jackson AS, eds. Drugs affecting lipid metabolism. Risk factors and future directions. Dordrecht: Kluwer Academic Publishers, 1996:591-7.
59. Pfohl M, Naoumova RP, Klass C, Knisei W, Jakober B, Risler R, Thompson GR. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor. J Lipid Res 1994;35:1946-55.
60. Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, Takeda R, Takegoshi T, Wakasugi T, Ueda K, Miyamoto S, Watanabe A, Oota M. Effect of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein apheresis. Atherosclerosis 1988;72: 183-8.